| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | IL17RA; IL17R; IMD51; CANDF5; CDw217; IL-17RA; hIL-17R |
| Entrez GeneID | 23765 |
| clone | 6H1B1 |
| WB Predicted band size | 96.1kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD217 (AA: extra 33-320) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD217(IL-17RA)抗体的3篇代表性文献示例，内容基于典型研究领域概括，供参考：
---
1. **文献名称**: *Therapeutic targeting of IL-17RA with a monoclonal antibody alleviates psoriasis-like inflammation in preclinical models*
**作者**: Smith A, et al.
**摘要**: 研究开发了一种靶向IL-17RA(CD217)的人源化单克隆抗体，通过阻断IL-17A/F介导的信号通路，显著减轻小鼠银屑病模型的皮肤炎症和角质化异常，提示其作为银屑病治疗的潜在药物。
2. **文献名称**: *Structural characterization of a neutralizing anti-IL-17RA antibody and its epitope mapping*
**作者**: Zhang L, et al.
**摘要**: 通过X射线晶体学解析了抗IL-17RA抗体的结合表位，发现其通过结合IL-17RA的胞外域关键区域抑制IL-17A/IL-17RC复合物形成，为优化抗体药物设计提供了结构基础。
3. **文献名称**: *IL-17RA signaling in airway epithelial cells promotes neutrophilic asthma*
**作者**: Jones R, et al.
**摘要**: 利用CD217抗体阻断实验证明，IL-17RA在气道上皮细胞中驱动中性粒细胞募集和炎症因子释放，提示靶向该受体可能对中性粒细胞型哮喘具有治疗价值。
---
**备注**：以上文献为示例，实际引用需根据具体研究内容检索PubMed或Google Scholar等数据库获取真实文献。若需精准推荐，请提供更多研究背景或目标(如疾病方向、抗体类型等)。
CD217. also known as interleukin-17 receptor A (IL-17RA), is a key component of the IL-17 receptor family, which mediates pro-inflammatory signaling in immune responses. As the common subunit shared by receptors for IL-17A, IL-17F, and other IL-17 family cytokines, CD217 plays a critical role in host defense and inflammatory diseases. It is expressed on epithelial cells, fibroblasts, and immune cells, facilitating signaling cascades that activate NF-κB and MAPK pathways, driving the production of inflammatory mediators like cytokines and chemokines.
CD217 antibodies are tools designed to target this receptor, either to block IL-17 signaling for therapeutic purposes or to study its biological functions. Dysregulated IL-17/CD217 signaling is implicated in autoimmune conditions such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease. Therapeutic anti-CD217 antibodies aim to inhibit pathogenic inflammation by preventing IL-17 binding or receptor activation. Research-grade antibodies are widely used in immunohistochemistry, flow cytometry, and functional assays to explore receptor expression, ligand interactions, and downstream effects.
The development of CD217-targeting biologics highlights its clinical relevance, though most approved IL-17 inhibitors (e.g., secukinumab) currently target the cytokine IL-17A rather than the receptor itself. Ongoing studies continue to evaluate CD217 as a potential therapeutic target for immune-mediated disorders.
×
